These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond. Kudo M World J Gastroenterol; 2019 Feb; 25(7):789-807. PubMed ID: 30809080 [TBL] [Abstract][Full Text] [Related]
6. The New Era of Systemic Treatment for Hepatocellular Carcinoma: From the First Line to the Optimal Sequence. Cerreto M; Cardone F; Cerrito L; Stella L; Santopaolo F; Pallozzi M; Gasbarrini A; Ponziani FR Curr Oncol; 2023 Sep; 30(10):8774-8792. PubMed ID: 37887533 [TBL] [Abstract][Full Text] [Related]
7. Review article: new therapeutic interventions for advanced hepatocellular carcinoma. Bangaru S; Marrero JA; Singal AG Aliment Pharmacol Ther; 2020 Jan; 51(1):78-89. PubMed ID: 31747082 [TBL] [Abstract][Full Text] [Related]
8. Role of immunotherapy in the management of hepatocellular carcinoma: current standards and future directions. Weinmann A; Galle PR Curr Oncol; 2020 Nov; 27(Suppl 3):S152-S164. PubMed ID: 33343209 [TBL] [Abstract][Full Text] [Related]
9. First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination. Tella SH; Kommalapati A; Mahipal A; Jin Z Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740326 [TBL] [Abstract][Full Text] [Related]
10. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma. Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299 [TBL] [Abstract][Full Text] [Related]
11. Systemic therapies for hepatocellular carcinoma: the present and the future. Celsa C; Giuffrida P; Stornello C; Grova M; Spatola F; Rizzo GEM; Busacca A; Cannella R; Battaglia S; Cammà C; Cabibbo G Recenti Prog Med; 2021 Feb; 112(2):110-116. PubMed ID: 33624623 [TBL] [Abstract][Full Text] [Related]
12. Emerging agents and regimens for hepatocellular carcinoma. Zhu XD; Sun HC J Hematol Oncol; 2019 Oct; 12(1):110. PubMed ID: 31655607 [TBL] [Abstract][Full Text] [Related]
13. Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life. Agirrezabal I; Brennan VK; Colaone F; Shergill S; Pereira H; Chatellier G; Vilgrain V Adv Ther; 2022 May; 39(5):2035-2051. PubMed ID: 35279814 [TBL] [Abstract][Full Text] [Related]
14. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma. Xing R; Gao J; Cui Q; Wang Q Front Immunol; 2021; 12():783236. PubMed ID: 34899747 [TBL] [Abstract][Full Text] [Related]
15. Systemic Treatment for Advanced Hepatocellular Carcinoma. Bouattour M; Mehta N; He AR; Cohen EI; Nault JC Liver Cancer; 2019 Oct; 8(5):341-358. PubMed ID: 31768344 [TBL] [Abstract][Full Text] [Related]
16. Navigating the new landscape of second-line treatment in advanced hepatocellular carcinoma. Rimassa L; Wörns MA Liver Int; 2020 Aug; 40(8):1800-1811. PubMed ID: 32432830 [TBL] [Abstract][Full Text] [Related]
17. Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma. Piñero F; Tanno M; Aballay Soteras G; Tisi Baña M; Dirchwolf M; Fassio E; Ruf A; Mengarelli S; Borzi S; Fernández N; Ridruejo E; Descalzi V; Anders M; Mazzolini G; Reggiardo V; Marciano S; Perazzo F; Spina JC; McCormack L; Maraschio M; Lagues C; Gadano A; Villamil F; Silva M; Cairo F; Ameigeiras B; Ann Hepatol; 2020; 19(5):546-569. PubMed ID: 32593747 [TBL] [Abstract][Full Text] [Related]
18. Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update. Kudo M Liver Cancer; 2020 Dec; 9(6):640-662. PubMed ID: 33442538 [TBL] [Abstract][Full Text] [Related]
19. Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients. Persano M; Rimini M; Tada T; Suda G; Shimose S; Kudo M; Cheon J; Finkelmeier F; Lim HY; Presa J; Masi G; Yoo C; Lonardi S; Tovoli F; Kumada T; Sakamoto N; Iwamoto H; Aoki T; Chon HJ; Himmelsbach V; Niizeki T; Montes M; Vivaldi C; Soldà C; Stefanini B; Hiraoka A; Sho T; Nishida N; Steup C; Iavarone M; Di Costanzo G; Marra F; Tamburini E; Cabibbo G; Foschi FG; Silletta M; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Campani C; Amadeo E; Rossari F; Burgio V; Cascinu S; Scartozzi M; Casadei-Gardini A Eur J Cancer; 2023 Aug; 189():112933. PubMed ID: 37385069 [TBL] [Abstract][Full Text] [Related]
20. [New Systemic Therapies for Advanced Hepatocellular Carcinoma]. Kim DY Korean J Gastroenterol; 2019 Jan; 73(1):10-15. PubMed ID: 30690953 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]